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bstract
The possibility of preparation of ophthalmic drug delivery systems using compressed anti-solvent technology was evaluated. Eudragit RS 100
nd RL 100 were used as drug carriers, acetazolamide was the model drug processed. Compressed anti-solvent experiments were carried out as
semi-continuous or a batch operation from a liquid solution of polymer(s) + solute dissolved in acetone. Both techniques allowed the recovery
f composite particles, but the semi-continuous operation yielded smaller and less aggregated populations than the batch operation. The release
ehaviour of acetazolamide from the prepared microparticles was studied and most products exhibited a slower release than the single drug.
oreover, the release could be controlled to some extent by varying the ratio of the two Eudragit used in the formulation and by selecting oner the other anti-solvent technique. Simple diffusion models satisfactorily described the release profiles. Composites specifically produced by
emi-continuous technique have a drug release rate controlled by a diffusion mechanism, whereas for composites produced by the batch operation,
he polymer swelling also contributes to the overall transport mechanism.
2006 Elsevier B.V. All rights reserved.
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. Introduction
Controlled drug delivery products using biocompatible or
iodegradable polymers, have received considerable attention in
he last years. In general, these substances provide a better con-
rolled rate of assumption of the drug by the body improving its
herapeutic action. In fact, there is a growing interest of the phar-
aceutical industry in the development of these systems (Heller,
996). Meanwhile, intensive world-wide research related to the
pplication of high-pressure and supercritical fluids in the field
f particle formation, encapsulation and impregnation of poly-
eric matrixes has proven the efficiency of SCF-technology
o generate improved delivery systems (Reverchon, 2002; Jung
nd Perrut, 2001; Vemavarapu et al., 2005). Supercritical fluid
∗ Corresponding author. Fax: +33 1 4940 3414.
E-mail addresses: rduarte@itqb.unl.pt (A.R.C. Duarte),
ubra@limhp.univ-paris13.fr (P. Subra-Paternault).
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oi:10.1016/j.ijpharm.2006.09.041echnology has became a very attractive alternative to the con-
entional processes due to the strict international regulations
hat rigorously control the presence of organic solvents in prod-
cts for medical or pharmaceutical applications. This technology
arrants a better removal of these solvents without exposing
rugs to high temperatures which may degrade them (a dry
olid product is easily obtained, just by manipulating pressure).
urthermore, supercritical carbon dioxide has major advantages
hen compared to most traditional solvents: it is non-toxic,
on-flammable and not expensive. Carbon dioxide can also be
ecovered and reused, and therefore, do not contribute to the
reenhouse effect. Because of all these advantages, supercrit-
cal processes are often referred and classified as “green” and
environmental friendly” processes (CPMP/ICH/283/95, 1997).
The CO2 anti-solvent technique is one of the techniques com-
only used to prepare new drug delivery systems. The technique
akes advantage of the anti-solvent effect of supercritical CO2 to
recipitate the substrate(s) initially dissolved in a liquid solvent.
hen performed in a semi-continuous mode (SAS), it is possible
rnal of Pharmaceutics 332 (2007) 132–139 133
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o control the morphology, size and size distribution of the par-
icles by manipulating process variables, such as temperature,
ressure and flow rate (Reverchon and Adami, 2005; Subra and
estin, 1999). In a batch mode (GAS, for gaseous anti-solvent),
he compressed anti-solvent is added to a given volume of liq-
id solution until the final pressure is reached (Subra and Jestin,
999). Although examples of drug delivery systems produced
y batch are scare, this mode offers larger times for precipi-
ation and/or interactions between drug and polymer than the
emi-continuous operation, giving potential for formulations of
ifferent characteristics.
Controlled drug delivery occurs when a polymer/drug sys-
em is designed to release the drug in a predetermined manner.
he main purpose of these release systems is to achieve a more
ffective therapy, that is, a delivery profile that would yield a
igh blood level of the drug over a long period of time, avoid-
ng the large fluctuations in drug concentration and reducing the
eed of several administrations (Brannon-Peppas, 1997).
Glaucoma is a serious eye disease that can lead to irreversible
lindness. Glaucoma is a group of ophthalmic disorders charac-
erized by an increase in intraocular pressure, which results in
amage to the optic nerve and visual field disturbances. Agents
sed to treat glaucoma are designed to decrease intraocular
ressure. Nevertheless, these drugs present severe side effects
herefore, there is an urgent need to develop new drug deliv-
ry systems. Various classes of drugs used in the treatment of
laucoma include, among others, carbonic anhydrase inhibitors
CAIs). Acetazolamide (N-5-sulfamoyl-1,3,4-thiadiazol-2-yl)-
cetamide (Fig. 1) is a CAI and has been an integral part of
nti-glaucoma treatment for more than 40 years (Kaur et al.,
002).
Modern sustained release dosage forms require excipients
hat can ensure a release rate of the active drug, which is
eproducible in a narrow range. Eudragit® (Fig. 2) polymers
ulfill these requirements to a very high extend and enable
esearch and development of tailor-made solutions (Anon, 2006,
ttp://www.roehm.de/). The Eudragit® grades for sustained
elease formulations are based on copolymers of acrylate and
ethacrylates with quaternary ammonium groups as functional
roups as well as ethylacrylate methylmethacrylate copolymers
ith a neutral ester group. Eudragit® RS and RL are water-
nsoluble, nevertheless they are both swellable, that is, perme-
ble to water, representing thus interesting materials for the
ispersion of drugs (Pignatello et al., 2003). This permeability
s due to the quaternarium ammonium groups present in their
Fig. 1. Chemical structure of acetazolamide.
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(Fig. 2. Chemical structure of Eudragit®.
tructure. The Eudragit® RL-types are highly permeable while
he Eudragit® RS-types are poorly permeable; therefore, release
rofiles can be varied by mixing RL and RS types in different
atios.
Nanoparticle coating and encapsulation of silica particles
ith Eudragit® has been successfully described by Wang et
l. (2004). Furthermore, the preparation of Eudragit® micro-
pheres containing acetazolamide using the solvent evaporation
ethod was appraised by Haznedar and Dortunc¸ (2004). In this
tudy, the possibility of preparing ophthalmic drug delivery sys-
ems using supercritical anti-solvent technology was evaluated.
udragit® RS 100 and RL 100 were used as drug carriers and
cetazolamide was the drug processed. The experiments were
erformed at different operational conditions and with different
ompositions of polymer.
. Experimental
.1. Materials
Eudragit RL 100® and RS 100® from Degussa were kindly
upplied by Socie´te´ de Produits Chemiques Industriels. Acetazo-
amide (N-5-sulfamoyl-1,3,4-thiadiazol-2-yl)-acetamide, CAS
59-66-5] (99% purity), was purchased from Sigma–Aldrich.
cetone CAS [67-64-1] (99.8% purity) was purchased from
rolabo (France). CO2 (99.5%, industrial grade) was obtained
rom Air Liquide (France). All chemicals were used without any
urther purification.
.2. Experimental procedure
.2.1. Semi-continuous anti-solvent technique
The experimental work was performed at a laboratory scale.
he apparatus is schematically presented in Fig. 3. Experiments
ere performed with the standard procedure already described
y Vega-Gonza´lez et al. (2004). The apparatus works in a semi-
ontinuous co-current mode, in which the CO2 anti-solvent and
he liquid solution are separately fed to the top of the precipitator
nd are continuously discharged from the bottom.
The spray chamber (2) consists of a high-pressure vessel
Autoclave Engineers), 5 cm i.d. × 25 cm long with sapphire
134 A.R.C. Duarte et al. / International Journal of Pharmaceutics 332 (2007) 132–139
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diameter. The stirring rate was set at 505 rpm. The CO2, deliv-
ered by a high-pressure pump, is introduced into the solution
through the turbine. At the vessel bottom, shut off and meter-
ing valves allow for discharging the solution and to regulate theig. 3. Experimental apparatus: (1) liquid solution pump; (2) high-pressure v
icrometering valve; (8)separator.
indows at three different levels allowing a visual observation
f both the spray and the precipitation. At the vessel bottom, the
recipitated powder is collected onto a membrane filter placed
n top of a stainless steel filter of 2m porosity. The CO2
as cooled by flowing through a cold water + ethanol bath (3)
nd then was pumped at constant flow by using a reciprocat-
ng LEWA (EK3) pump (4). Prior to entering the precipitation
hamber, it flowed through a second water bath (5) for an heat-
ng at the vessel temperature. The pressure inside the vessel was
ontrolled downstream with a metering valve (7), and the tem-
erature was controlled by heating jackets (Watlow). Acetone
olutions of solutes were sprayed into the precipitation chamber
y means of a reciprocating dual-piston minipump (Milton Roy
DC).
Once the temperature of the vessel had attained the desired
alue, the CO2 was pumped to the vessel until the desired pres-
ure was reached; a constant flow was further maintained via
he metering valve. The solution was introduced into the pre-
ipitation chamber through a spray-type nozzle of 100m, at a
ypical flow rate of 1.1 mL/min. After leaving the precipitator,
he CO2/acetone solution was depressurised across the metering
alve and separated in a homemade cyclonic separator (8). Once
he desired volume of solution was sprayed, fresh CO2 passed
hrough the chamber in order to dry the precipitated powder.
fter approximately 40 min of purging with CO2, the vessel was
lowly depressurized at the experimental temperature. Tubing
nd valves after the vessel were heated to prevent freezing due
o CO2 expansion, and they were flushed with acetone between
ach experiment.
.2.2. Batch anti-solvent technique
The set-up is presented schematically in Fig. 4. The apparatusnd the procedure were previously described (De Gioannis et al.,
004).
Briefly, the crystalliser is a stainless steel vessel of 20 cm in
eight and 4.3 cm of internal diameter, with three sapphire win-
F
1
s; (3) CO2 cooling bath; (4) CO2 pump; (5) CO2 heating bath; (6) valve; (7)
ows to allow visual observations. The tank is equipped with
our baffles that preclude the generation of a central vortex.
he temperature is measured by a type K thermocouple with
n accuracy of 1 ◦C, and controlled by electric resistances. The
ressure is measured by a pressure sensor with an accuracy of
.1 MPa. The stirring is provided by a magnetically coupled
tirrer with a eight-bladed Rushton-type turbine of 2.5 cm inig. 4. (1) CO2 cylinder; (2) cooling unit; (3) CO2 pump; (4) flow meter; (5 and
0) valve; (6 and 11) metering valve; (7) stirrer; (8) crystalliser; (9) turbine; (12)
olution recovery.
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At the investigated conditions of 82.7 bar and 32.3 C, it was
assumed that the jet break-up generated droplets of polymer
solution with entrapped nanoparticles, and that the subsequent
crossing over the equilibrium boundary initiated the gelation ofA.R.C. Duarte et al. / International Jou
rystalliser pressure during the final steps. A stainless steel frit
f 5m in porosity and a membrane of 0.22m are located at
he vessel bottom to collect the precipitated powder.
The procedure consisted in four steps, that are, (I) pressur-
zation up to the desired final pressure by addition of CO2, (II)
ischarge of the solution, (III) crystals drying and (IV) depres-
urization. After the initial loading of the vessel with 65 mL of
he polymer + drug solution and the obtaining of a stable tem-
erature, CO2 was introduced by opening the inlet metering
alve until that the vessel pressure equilibrated the CO2-cylinder
ressure. The pump was further activated to continue the intro-
uction up to the desired pressure. The CO2 feed was regulated
round 3 bar/min (i.e. 12 g/min) for the experiments reported
ere, through the metering valve and the pump frequency. Upon
he addition of CO2, the solvating ability of the newly formed
ixture decreased and caused the solute precipitation. The dis-
harge was carried out immediately after the pressurization step;
he aim of the step is to wash out the CO2 + acetone mixture that
ontains the non-precipitated part of solute. The step was car-
ied out by regulating the exit flow and compensating by fresh
O2, and lasted about 60 min. The CO2 flow was further main-
ained during 45 min to dry the precipitates. Depressurization
as finally performed by venting CO2 by the exit line. Crystals
ere collected for subsequent analysis; the ratio of the collected
mount to the initial amount of components dissolved in the
iquor defined the yield.
.2.3. Particle characterization
.2.3.1. Scaning electron microscopy—SEM. The morphology
f polymer samples was analysed and imaged by scanning elec-
ron microscopy (SEM, Leica 5440) after sputter coating with
old-palladium to a thickness of approximately 90 A˚.
.2.3.2. Particle size and size distribution. The particle size and
ize distribution of the prepared microparticles were measured
y Laser diffraction spectrometry (Coulter LS 130, Coulter Elec-
ronics). The dried powder samples were suspended in deionised
ater with a surfactant solution (Coulter Dispersant, Coulter)
nd sonicated for 1 min with an ultra-sound probe (500 W,
ibra Cell, Sonics & Materials, Inc.) before measurement. The
btained homogeneous suspension was determined for the vol-
me mean diameter, size distribution and polydispersity. Each
ample was analysed three times.
.2.3.3. In vitro drug release studies. Particles (20 mg) were
uspended in 40 mL of phosphate buffer solution (pH 7.4) and
imulated gastric fluid without pepsin (pH 1.2) stirred at 150 rpm
t 37 ◦C. 0.5 mL aliquots were withdrawn at predetermined time
ntervals and the same volume of fresh medium was added to the
uspension. The samples were filtered (0.45m, millipore fil-
ers) and analysed by HPLC (ThermoFinnigan Surveyor consist-
ng of a quaternary pump, autosampler and diode array detector).
column (Merck Lichrospher 100 RP-18e, 250 mm × 4 mm,
m; cat. No. 1.50995) kept at room temperature, was used in
socratic conditions with a mobile phase consisting of sodium
cetate trihydrated in water:methanol:acetonitrile (950:20:30),
H 4.0. The flow rate was 1.5 mL/min and the volume of injec-
F
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ion was 20L. Quantitation was performed at 254 nm by exter-
al standard calibration. The total mass of released drug in each
oment of the experiment was calculated taking into account
he aliquots taken and the dilution produced by addition of fresh
uffer.
. Results and discussion
Preliminary experiments were carried out in order to precip-
tate pure polymers (Eudragit RS or RL) or a mixture of them
n the ratio of 50:50, without acetazolamide. Attempts were not
uccessful since the polymer created a film-like structure on
he cylinder walls and did not precipitate as a powder. Nev-
rtheless, Eudragit S100, which is an anionic polymer based
n methacrylic acid esters has been precipitated using a simi-
ar apparatus to the one described from an acetone solution at
5 bar and 35 ◦C (Fig. 5). The structural difference in these types
f Eudragit is what probably causes the discrepancy in the results
btained.
This observed behaviour is in accordance with the few
ublished results reporting precipitation of pure polymers or
xamples of encapsulation/coating with Eudragit assisted by
upercritical techniques. Chattopadhyay and Gupta (2002) used
udragit RS 100 for the production of magnetically respon-
ive particles. Precipitation of the pure polymer have led to
he formation of agglomerated spherical but flattened particles.
he appearance was attributed to the decrease of the poly-
er glass transition temperature in the presence of supercritical
O2, which resulted in polymer softening. The main difference
etween their conditions and ours resided in the way of introduc-
ng the solution and CO2 into the vessel, and this might explain
he different precipitation behaviour. The polymer swelling was
xploited by Wang et al. (2004) for the purpose of coating silica
ith Eudragit RL 100 by supercritical anti-solvent technique.
◦ig. 5. SEM image of Eudragit S100 precipitated by SAS (semi-continuous
ode).
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Table 1
Composites processed by the semi-continuous operation
#Run Polymer Drug Yield (%) Particle size (m)
1 Eudragit RL 100 ACTZ 77 17.85
2 Eudragit RS 100 ACTZ 63 23.88
3 RL 100 + RS 100 (50:50) ACTZ 66 21.32
4 RL 100 + RS 100 (70:30) ACTZ 70.7 19.76
5 RL 100 + RS 100 (30:70) ACTZ 74.8 17.04
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tonditions: temperature of 37 ◦C, pressure of 83 bar, CO2 flow rate of
15 mL/min, solution flow rate ∼1.1 mL/min. ACTZ = acetazolamide; the
eported particle size is the mean size of the distribution.
he polymer around the particles. Since the experimental con-
itions used in our study were 37 ◦C and 83 bar, the obtained
lm-like structure can thus be explained by the swelling of the
olymer at these conditions. Another type of Eudragit, Eudragit
100 (tertiary ammonium groups) was processed in the presence
f CO2 by the solution enhanced dispersion technique (SEDS)
nd no well-defined particles were obtained owing to its low
g (Juppo et al., 2003). The combination of pressurized carbon
ioxide with holt melt extrusion was also carried out (Verreck
t al., in press), and it was again stated that CO2 acted as a
lasticizer for Eudragit E 100.
.1. Precipitation of acetazolamide-loaded particles
A first set of experiments was designed in the semi-
ontinuous apparatus, to evaluate the effect of pressure, temper-
ture and CO2 flow rate upon the recovery of powder; conditions
ere settled as proposed by Wang et al. (2004). The processed
aterials were a mixture of acetazolamide and one polymer.
he results obtained were presented elsewhere (Vega-Gonza´lez
t al., 2005). Briefly, the morphology of the particles were not
trongly affected by the operational conditions, and we con-
luded that conditions to achieve a higher yield and smaller
article diameter in a semi-continuous operation were a tem-
erature of 37 ◦C, a pressure of 83 bar and a CO2 flow rate of
15 mL/min. The second set of experiments was then dedicated
o test various formulations of drug and polymers. Conditions
nd results of experiments are summarized in Table 1 for the
emi-continuous investigations. In these experiments, mixtures
f Eudragit RS and RL (50:50; 70:30 and 30:70) were coprecip-
tated with acetazolamide. The drug concentration was constant
nd fixed at ∼8.2 mg/mL and the polymers:drug ratio was of 2:1
w:w).
Particles produced by the semi-continuous mode were recov-
red as a powder made of spherical and elongated structures, as
hown in Fig. 6. The composition of the polymer mixture does
t
i
i
able 2
omposites processed by the batch operation
Run Mixture CACTZ (mg/mL)
ACTZ + RS + RL 8.2
ACTZ + RS + RL 7.3
ACTZ + RS + RL 4.9
onditions: stirring at 505 rpm; CO2 feed ∼3.1 bar/min; (Eudragit RL + Eudragit RS)
he D10 and D90 of the PSD.ig. 6. SEM image of the precipitated acetazolamide + Eudragit blend (run #4)
y a semi-continuous operation.
ot influence notably the yield or the mean particle size, since
here is no straight tendency of those characteristics with the RL
r RS content. However, it is worth noting that the presence of
he drug allows for the precipitation of the polymer, whereas its
rocessing as pure have led to a film deposition onto the vessel
urface. Among the formulations proposed, the composition of
0:70 RL:RS was found to combine the smaller particle size and
he higher yield. The batch operation was thus carried out with
hat mixture, keeping also the polymer:drug ratio to 2:1.
When the precipitation was carried out in the batch mode
Table 2), the recovered powder showed large agglomerates,
ade of rods embedded within a continuous film. The decrease
f the operating temperature from 40 to 27 ◦C and of the over-
ll species concentration as well decreased the aggregation and
he particle size range (run #8, Fig. 7). Compared to the semi-
ontinuous mode, the batch operation produced particles of
arger size and more dispersed with a low yield in the 40% range;
t is thus suggested that the semi-continuous mode is preferable
or the precipitation of ACTZ composites.
.2. Release studies
As the main goal of this work was to prepare a controlled
elease system for acetazolamide, the solubility of the pure drug
as first evaluated in two biological fluids, that are, simulated
astric fluid (pH 1.2) and PBS (pH 7.4) simulating the intestinal
nvironment. In Fig. 8, the solubilization of acetazolamide as a
unction of time is presented for the two media.As it can be observed, the pure drug is totally dissolved in
he two media in 4 h. However, acetazolamide solubilizes faster
n a neutral environment than in the simulated gastric fluid and
ts complete dissolution is thus achieved in 1.5 h instead of 4 h.
T; Pf Yield (%) Particle size (m)
40 ◦C; 90 bar 37.3 255–711
32 ◦C; 61 bar 45.7 117–498
27 ◦C; 57 bar 36.4 76–306
: ACTZ ratio of 2:1; Eudragit RL:RS ratio of 30:70. The range of size given is
A.R.C. Duarte et al. / International Journal of Pharmaceutics 332 (2007) 132–139 137
Fig. 7. SEM image and particle size distribution (vol.%) of acetazolamide +
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dig. 8. Release profiles of the pure drug, acetazolamide () pH 1.2 and () pH
.4.
his fast dissolution rate is clinically undesirable as it does not
romote the contact of the drug with the mucosal membranes
ver a time sufficient enough to be absorbed, so the drug will
e “washed out” of the body. Therefore a system that enables a
ustained release of the drug is of great interest for the delivery
f acetazolamide.
The comparison of the drug released from the microspheres
repared by semi-continuous operation and involving only one
olymer (Eudragit RS or Eudragit RL) is presented Fig. 9.
lthough the two formulations induced a slower release of the
rug, Eudragit RS 100 obviously ensured a more uniform release
ver a longer time than Eudragit RL 100.
ig. 9. Release profiles (pH 1.2) of the (*) pure drug and the systems () Eudragit
S 100 + acetazolamide (run #2) and (♦) Eudragit RL 100 + acetazolamide (run
1).
t
T
b
(
F
#Eudragit blend (run #8) precipitated by batch anti-solvent operation.
The release profiles obtained for the two media, i.e. at pH 1.2
nd 7.4, exhibited the same behaviour than the pure drug, i.e.,
he release of the drug is faster in a neutral environment than in
n acidic one (Fig. 10).
The release behaviour, either at pH 1.2 or pH 7.4, depends
hus greatly on the type of polymer used in the formulation.
ndeed, there is a large difference in the acetazolamide release
rom Eudragit RS 100 or from Eudragit RL 100, as already
llustrated in Fig. 9. Acetazolamide release from Eudragit RS
00 miscrospheres was much slower and incomplete when com-
ared to the spheres prepared with Eudragit RL 100 in which
lmost 80% of the drug is released after 3 h. This discrepancy in
he release profiles is due to the functionality of the quaternary
mmonium groups. As stated earlier, the Eudragit® RS-types are
oorly permeable, therefore the diffusion of the drug out of the
ystem is slower, leading to lower drug concentrations in solu-
ion. Similar results were obtained by Haznedar and Dortunc¸
2004) when the same microspheres were prepared by a con-
entional technique.
The preparation of polymer blends co-precipitated with
cetazolamide can create tailor-made solutions with the desired
rug release profile. By supercritical semi-continuous technique,
hree blends were precipitated in the presence of acetazolamide.
he drug load was kept constant so that the influence of the
lend composition upon the release rate could be evaluated
Fig. 11).
ig. 10. Release profiles of the system Eudragit RS 100 + acetazolamide (run
2) () pH 1.2 and () pH 7.4.
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(see PSD profile reported in Fig. 7). Therefore, it is postulatedFig. 11. Release profiles (pH 1.2) of the systems described
From the experiments performed with the polymers alone
nd the co-precipitation of polymer blends, we can conclude
hat it is possible to control the drug release from the particles
roduced if the ratio between the two polymers Eudragit RS and
L is varied. In Fig. 11 it is evidenced that an increase of the
udragit RL percentage enhances the release of the drug in the
queous media. The same behaviour was observed with PBS at
H 7.4.
The release profiles of particles produced by the batch opera-
ion were also studied in the two media. Samples were produced
rom same polymer blends of Eudragit RL and RS of 30:70, but
ith different conditions of temperature and overall concentra-
ion. Fig. 12 shows the behaviour at pH 1.2; comparison with the
issolution profile of pure acetazolamide, and the release profile
f a semi-continuous sample (run #5) is also provided. Among
he batch samples, the agglomeration and the particle size of
he powder obviously influenced the release rate of the drug.
articles prepared at higher pressure and temperature present
arge agglomerates and therefore, the drug release is slower.
ike previously, the formulation with a polymer blends enable
sustained release of the drug into the aqueous media, but the
CTZ release was faster from the batch composite particles thanrom the semi-continuous ones.
To better understand the drug release mechanism of the sys-
ems prepared, the Fick’s law of diffusion and the Power law
ig. 12. Release profiles (pH 1.2) of the system acetazolamide + (Eudragit RS
00 (70%) + Eudragit RL 100 (30%)) prepared by batch operation in various con-
itions (run #6: (), #7: (), #8: () or obtained by semi-continuous operation
run #5: (♦)); the dissolution profile of pure drug (–x–) is given for comparison.
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ce table, where the ratio of the two polymers is evidenced.
ere applied to fit the release profiles (Siempmann and Peppas,
001). The Fick’s law is a special case of the Power law, when
he release exponent is 0.5. For the release range Mt/M∞ below
0%, Mt/M∞ versus tn, can be applied. Both the Fick’s law and
he Power law were found to fit well the release data of samples
roduced by the semi-continuous operation (Fig. 13, run #5).
he release exponents n obtained were very closed to the values
f 0.43–0.45 that indicate a diffusion-controlled drug release in
ase of spherical or cylindric samples (Siempmann and Peppas,
001). The Power law enables to determine the kinetic constants
ssociated to the release of the drug from the produced sys-
ems. The kinetic constant for the release of acetazolamide from
udragit RS was 0.26 and from Eudragit RL was 0.31. When a
lend of the two polymers were co-precipitated with the drug, the
alues were within these two limits as expected. The composites
roduced by batch operation were found to exhibit a different
ehaviour. The fit of release profile with the Power law gave
elease exponents n in the range of 0.56–0.61, specially at pH
.2 (Fig. 13, run #6). However, the limits set to differentiate the
echanisms apply only if the particles are monodispersed, that
s hardly the case of particles produced by the batch operationhat the release mechanism from batch-samples is due to both
iffusion and swelling.
ig. 13. Power law (pH 1.2) of the systems acetazolamide + (Eudragit RS 100
70%) + Eudragit RL 100 (30%)) prepared by batch (run #6: ()) or semi-
ontinuous operation (run #5: (♦)).
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. Conclusions
The preparation of acetazolamide composite particles for
phthalmic drug delivery was successfully performed with the
se of CO2 as anti-solvent. Conditions that combined a produc-
ion rate in the range of 70%, a particle size distribution between
and 40m and slowest release of the drug were obtained by
he semi-continuous operation, carried out at 83 bar, 37 ◦C with
mL/min liquid flow and 15 mL/min CO2 flow. Particles pre-
ared by the batch operation had a larger mean size diameter
nd a larger size distribution than semi-continuous samples.
The rate of the release of the drug into aqueous media could
e controlled to some extend by the preparation of these parti-
les, either by using two versions of the anti-solvent technique,
r by varying the ratio of two types of Eudragit as polymer blend.
ormulations enriched in Eudragit RS lead to a slower release
f acetazolamide than those enriched in Eudragit RL, whereas
amples processed by batch exhibit faster profiles than those
rocessed by the semi-continuous mode. The compliance of
he release profiles of semi-continuous samples with the Power
aw suggests that the drug release is controlled by diffusion
echanism, and the derived kinetic constant is increasing as the
ontent of Eudragit RL in the polymer blend increases. For sam-
les produced by batch operation, their faster release despite a
arger particle size, their compliance with the Power law, and the
ncrease of the rate with a decrease of particle size, suggest that
he polymer swelling intervenes in the release transport although
iffusion is still predominant.
Therefore, various controlled release systems for the delivery
f acetazolamide was successfully prepared using a supercritical
nti-solvent process.
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